Funding: New Awards

James DiRenzo
Associate Professor
Cancer Mechanisms

  • NCI
    MicroRNA expression patterns in human breast cancer specimens

Christopher H. Lowrey
Professor of Medicine
Molecular Therapeutics

    A Phase II study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy plus dasatinib and continuation therapy with dasatinib alone in newly diagnosed patients with core binding factor acute myeloid leukemia(AML)
    A Phase II study incorporating sorafenib into the therapy of patients ≥ 60 years of age with FLT3 mutated acute myeloid leukemia (AML)